NSEShareholders meeting14 Jul 2026 · 14 Jul 2026, 07:44 pm
Shareholders meeting
Ind-Swift Laboratories Limited · INDSWFTLAB
✦ AI SummaryM&A
Ind-Swift Laboratories Limited has informed the Exchange regarding Notice of Extraordinary General Meeting to be held on August 05, 2026, to consider issuance of up to 70,00,000 fully convertible warrants to an entity belonging to the 'promoter & promoter group' on preferential basis.
Analysis Scores
Earnings Impact2/10
Growth Catalyst4/10
Governance Concern6/10
Regulatory Risk5/10
Balance Sheet Risk4/10
Liquidity Impact3/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Ind-Swift Laboratories Limited has informed the Exchange regarding Notice of Extraordinary General Meeting to be held on August 05, 2026
Attachments (1)
📄pdf
Download →
INDSWFTLAB_14072026194317_Notice_of_EGM_Intimation.pdf
View document text
Ref: ISLL:CH:2026 Date: 14th July, 2026
The President The Vice President,
Corporate Relationship Department Listing Compliance Department,
BSE Limited National Stock Exchange of India Limited,
Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor
25th Floor, Dalal Street, Plot No. C/2, G-Block,
Mumbai 400 001 Bandra Kurla Complex, Bandra (E),
Mumbai 400 051
BSE Scrip Code: 532305 NSE Symbol: INDSWFTLAB
Subject : Notice of Extra-Ordinary General Meeting (“EGM”) of Ind-Swift Laboratories Limited
(“the Company”)
Dear Sir/Ma’am,
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the Securities and Exchange Board of
India (Listing Obligation & Disclosure Requirements) Regulation, 2015, as amended and any other applicable
provision, we are pleased to inform that the Extra Ordinary General Meeting (“EGM”) of the Members of Ind-
Swift Laboratories Limited (“the Company”) will be held on Wednesday, August 05, 2026 at 11:30 AM (IST)
through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”).
In compliance with provisions of the Companies Act, 2013, electronic copies of the Notice convening the EGM,
has been dispatched by e-mail to all the Members whose e-mail addresses are registered with the Company and/or
the Depository Participant. The Extra-Ordinary General Meeting Notice is also uploaded on the Company’s
website at the link https://www.indswiftgroup.com/investor-relations/notice-of-agm-egm/.
Pursuant to Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and
Administration Rules), 2014 and Regulation 44 of the SEBI (LODR) Regulations, 2015, the Company is providing
the facility to its members holding shares on cut-off date i.e. Wednesday, July 29, 2026 to exercise their right to
vote by electronic means on all or any of the business specified in the notice convening the EGM. (Copy enclosed)
The remote e-voting will be available during the following period:
Commencement of remote e-voting Sunday, 02nd August, 2026 (9:00 A.M. IST)
End of remote e-voting Tuesday, 04th August, 2026 (5:00 P.M. IST)
You are requested to take the same on your record.
Thanking you,
Yours faithfully,
For IND-SWIFT LABORATORIES LTD
PARDEEP VERMA
VP-CORPORATE AFFAIRS &
COMPANY SECRETARY
IND-SWIFT LABOPRATORIES LIMITED
CIN: L24232CH1995PLC015553
Registered Office: SCO:850, Shivalik Enclave, NAC, Manimajra, Chandigarh – 160101, India
Email: investor@indswiftlabs.com Website: www.indswiftgroup.com
Notice of Extra-Ordinary General Meeting
Notice is hereby given that the 01/2026-27 Extra-Ordinary General Meeting (“EGM”) of the members
of Ind-Swift Laboratories Limited ("the Company”) will be held on Wednesday, August 05, 2026, at
11:30 A.M. (IST) through video conferencing (“VC’’)/ other audio-visual means (“OAVM”) to transact
the following business:
SPECIAL BUSINESS:
Item No. 1: ISSUANCE OF UPTO 70,00,000 FULLY CONVERTIBLE WARRANTS TO AN
ENTITY BELONGING TO THE ‘PROMOTER & PROMOTER GROUP’ ON
PREFERENTIAL BASIS.
To consider, and if thought fit, to pass, the following resolution as Special Resolution:
“RESOLVED THAT pursuant to provisions of Sections 42, 62(1)(c) and other applicable provisions,
if any, of the Companies Act, 2013 (hereinafter referred to as the “Companies Act”) read with the
Companies (Prospectus and Allotment of Securities) Rules, 2014, as amended and the Companies
(Share Capital and Debentures) Rules, 2014, as amended and other relevant rules made there under
(including any statutory modification(s) or enactment(s) or re-enactment(s) thereof, for the time being
in force), enabling provisions in Memorandum and Articles of Association of the Company, provisions
of uniform listing agreement entered into with National Stock Exchange of India Limited (“NSE”) and
BSE Limited (“BSE”), where the equity shares of the Company are listed (collectively referred to as
“Stock Exchanges”), and in accordance with the guidelines, rules and regulations of the Securities and
Exchange Board of India (“SEBI”), as amended including the SEBI (Issue of Capital and Disclosure
Requirements) Regulations, 2018, as amended (“SEBI (ICDR) Regulations”), the SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), as
amended, SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 (“Takeover
Regulations”) as amended, and in accordance with other applicable rules, regulations, circulars,
notifications, clarifications and guidelines issued thereon, from time to time, by Ministry of Corporate
Affairs, SEBI and/or any other competent authorities, and subject to approvals, consents, permissions
and/or sanctions, as may be required from the Government of India, SEBI, Stock Exchanges, and any
other relevant statutory, regulatory, governmental authorities or departments, institutions or bodies and
subject to such terms, conditions, alterations, corrections, changes, variations and/or modifications, if
any, as may be prescribed by any one or more or all of them in granting such approvals, consents,
permissions and/or sanctions and which may be agreed to by Board of Directors of the Company
(hereinafter referred to as the “Board” which term shall be deemed to include any Committee, which
the Board has constituted or may hereafter constitute, to exercise one or more of its powers, including
the powers conferred hereunder), consent of the Members of the Company be and is hereby accorded
to the Board to create, issue, offer and allot, on a preferential basis, up to 70,00,000 (Seventy Lakh)
Fully Convertible Warrants (“Warrants”) at an issue price of Rs. 196/- (Rupees One Hundred and
Ninety-Six Only) each, determined in accordance with the provisions of Chapter V of SEBI ICDR
Regulations, fully convertible at an option of Warrant holder(s) in one or more tranches, within 18
(Eighteen) months from the date of its allotment into an equivalent number of fully paid-up equity
NOTICE OF EGM
shares of the face value of Rs. 10 each, for cash, aggregating up to Rs. 137,20,00,000 (Rupees One
Hundred Thirty-Seven Crore and Twenty Lakh Only) and to issue Fresh Equity shares on the
conversion of Warrants on such further terms and conditions as may be finalized by the Board of
Directors, to the below mentioned entity belonging to the ‘Promoter & Promoter Group’, for cash
("Proposed Allottee”):
Sr. Name of the Proposed Allottee Category of Proposed No. of Warrants
No. Allottee (up to)
1. E ssix Biosciences Limited Promoter & Promoter Group 70,00,000
Total 70,00,000
RESOLVED FURTHER THAT in terms of provisions of Chapter V of SEBI ICDR Regulations, the
‘Relevant Date’ for the purpose of determining the minimum issue price of Warrants proposed to be
allotted to the above-mentioned allottee shall be Monday, July 06, 2026, i.e. being the date, which is
30 days prior to the date of Extra-ordinary general meeting i.e. Wednesday, August 05, 2026.
RESOLVED FURTHER THAT aforesaid issue of Warrants shall be subject to the following terms
and conditions:
a) The conversion of warrants into equity shares shall happen at any time within a period of
Eighteen (18) months from the date of allotment of warrants in terms of SEBI ICDR
Regulations (the “Warrant Exercise Period”).
b) The Proposed Allottee(s) shall, on or before the date of allotment of Warrants, pay an amount
equivalent to at least 25% of the Warrant Issue Price fixed per Warrant, in terms of the SEBI
ICDR Regulations, 2018, which will be kept by the Company to be adjusted and appropriated
against the Warrant Issue Price of the Equity Shares. The balance of 75% of the Warrant Issue
Price shall be payable by the Warrant Holder at the time of exercising the Warrants.
c) Warrants being allotted to the Proposed Allottee, and the Equity Shares proposed to be allotted
pursuant to the conversion of these Warrants shall be under lock-in for such period as may be
prescribed under SEBI ICDR Regulations.
d) Warrants so allotted under this resolution and Equity shares
[Showing first 8,000 characters — download PDF for full document]